[Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation].
OBJECTIVE
To investigate the expression of IGF-IR and COX-2 in renal cell carcinoma(RCC). To explore the correlation among IGF-IR, COX-2 and PCNA expression.


METHODS
Immunohistochemical staining was performed to detect the expression of IGF-IR, COX-2 and PCNA in 64 cases of RCC.


RESULTS
The positive rates of IGF-IR expression and COX-2 expression were 60.9%(39/64) and 51.6%(33/64) in RCC respectively. The expressions of IGF-IR and COX-2 in RCC tissues were not related to the histological type of RCC (P>0.05), but they were related to and increased with the size and clinical stages of RCC (P<0.05). The expression of IGF-IR was related to pathological grades, but COX-2 was not. The expression of IGF-IR was positively related with the expression of COX-2 and PCNA respectively, but there was negative correlation between COX-2 and PCNA.


CONCLUSIONS
The experiment suggests that IGF-IR and COX-2 may produce a synergetic effect in oncogenesis and progression of RCC. Detection of these genes has positive effects on early diagnosis, malignancy determination, prognosis and treatment of RCC.
Sun
Hang
H
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. sunhang@fmmu.edu.cn
Wang
He
H
Qin
Wei-jun
WJ
Yang
Bo
B
Wang
Su-chun
SC
Jian
Bai-lu
BL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000473:pathology*; D049109:Cell Proliferation; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018809:Proliferating Cell Nuclear Antigen / Q000096:biosynthesis; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis*; D047368:Tumor Burden
D018809:Proliferating Cell Nuclear Antigen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D017526:Receptor, IGF Type 1